Along with the emerging of the new generation of insulin analogues (degludec and glargine U300) came the comparisons between these two insulins, mostly in terms of incidence of hypoglycaemia [13–16], and pharmacokinetic/pharmacodynamic (PK/PD) characteristics [13, 17, 18]. The gene discussed is INS; the disease is Hypoglycemia.